 |
Vol.60 No.7 contents | Japanese/English |
 | Full Text of PDF (456K) Article in Japanese |
- Original Article -
Relationship Between the Effect of Immune Checkpoint Inhibitors and Peripheral Differential Leukocyte Counts
Sakae Fujimoto1, Koichi Minato1, Ryoichi Onozato2, Atsushi Fujita21Department of Pulmonary Medicine, 2Department of Thoracic Surgery, Gunma Prefectural Cancer Center, Japan
Objective. The immune status of the tumor microenvironment (TME) in lung cancer patients influences the effect of immune checkpoint inhibitors (ICIs). The effective immune status of ICIs was examined using peripheral differential leukocyte counts. We also searched the relevant literature for data on the relationship between differential leukocyte counts in the peripheral blood and in tumor-infiltrating leukocytes in the TME. Method. Peripheral differential leukocyte counts at the time of ICI administration (day 1) and 42 days after ICI administration (day 43) in 83 cases of non-small cell lung cancer treated with ICIs alone at our hospital between February 2016 and October 2019 were included in a Cox regression analysis to identify factors associated with progression-free survival (PFS) and overall survival (OS). Results. Higher eosinophil counts in the peripheral blood on day 1 were associated with a significantly improved PFS, and higher monocytes were associated with significantly worse PFS and OS. Higher eosinophil and lymphocyte counts in the peripheral blood on day 43 were associated with significantly improved PFS and OS, and higher basophil and monocyte counts were associated with significantly worse PFS and OS. Conclusion. The effect of ICI treatment is related to the peripheral differential leukocyte counts.
key words: Immune checkpoint inhibitor, Eosinophil, Basophil, Monocyte, Lymphocyte
Received: June 3, 2020
Accepted: August 25, 2020
JJLC 60 (7): 958-965, 2020
